Skip to main content
Clinical Trials/IRCT2016122722134N4
IRCT2016122722134N4
Completed
Phase 2

Comparison in myocardial perfusion between the intracoronary versus intralesional eptifibatide administration during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction; A randomized clinical trial

Vice Chancellor for research of Isfahan University of Medical Sciences0 sites60 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
cardiovascular disease.
Sponsor
Vice Chancellor for research of Isfahan University of Medical Sciences
Enrollment
60
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice Chancellor for research of Isfahan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of ST elevation myocardial infarction (STEMI) as defined by chest pain suggestive for myocardial ischemia for at least 30 minutes before hospital admission and symptoms onset time was less than 12 hours with 1 mm ST segment elevation in 2 or more contiguous leads (for V1\-V3 ST elevation was 2 mm) simultaneously; These patients should also have three or more thrombus burden grade on the angiography. Thrombus burden was graded (G) as G0 \= no thrombus, G1 \= possible thrombus, G2 \= small (greatest dimension \= 1/2 vessel diameter), G3 \= moderate (\> 1/2 but \< 2 vessel diameter), G4 \= large (\= 2 vessel diameter), G5 \= unable to assess TB due to vessel occlusion; undergoing PCI; The consent of patients or their families to participate in the study; insensitivity to Eptifibatide
  • Exclusion criteria: Rescue PCI after thrombolytic therapy; Contraindications for antiplatelet such as bleeding disorder including gastrointestinal bleeding, hematuria, or known any bleeding tendency; thrombocytopenia (Platelet count\<100\.000/cm3\); recent stroke (less than 6 months) and cardiogenic shock

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials